Ardent Health Partners ARDT Trading Securities in Marketable Securities

Other financials

Revenue$1.6B+7.0%

Gross profit$1.6B+6.7%

Net income$39.9M-3.7%

EPS (diluted)$0.28-3.4%

Cash & equivalents$609.7M+23.2%

Total debt$1.2B+1.7%

Total equity$1.3B+13.8%

Total assets$5.3B+7.0%

Operating cash flow-$60.2M-143%

CapEx$28.1M+22.6%

Free cash flow-$88.3M-85.2%

Market cap$1.35B-27.8%

Enterprise value$1.91B-24.3%

P/E10×+1.7×

P/S0.2×-0.1×

Gross margin97.5%-0.1pp

Net margin2.1%-1.6pp

FCF margin3.4%+1.4pp

Return on equity10.7%-9.0pp

Debt / equity0.9×-0.1×

Current ratio2.1×0.0×

Reported directly by Ardent Health Partners in its filing.

Tagged under the XBRL concept us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount.

The official record: Ardent Health Partners’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and see it in context, right in your chat.

What is Ardent Health Partners's trading securities in marketable securities?: Ardent Health Partners (ARDT) reported trading securities in marketable securities of $18.8M in Q1 2026.